(Q46648097)

23 December 2017

title

Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes (English)

1 reference

23 December 2017

1 reference

4

1 reference

23 December 2017

Heljä-Marja Surcel

5

object named as

Heljä-Marja Surcel

1 reference

23 December 2017

8

Kari Syrjänen

1 reference

23 December 2017

author name string

Johanna Palmroth

1

1 reference

23 December 2017

Proscovia Namujju

2

1 reference

23 December 2017

Aline Simen-Kapeu

3

1 reference

23 December 2017

Marjo Tuppurainen

6

1 reference

23 December 2017

Merja Yliskoski

7

1 reference

23 December 2017

Matti Lehtinen

9

1 reference

23 December 2017

publication date

1 May 2010

1 reference

23 December 2017

published in

Infectious Diseases

1 reference

23 December 2017

volume

42

1 reference

23 December 2017

issue

5

1 reference

23 December 2017

page(s)

379-384

1 reference

23 December 2017

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Effectiveness of preventive human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Human papillomavirus infections with multiple types and risk of cervical neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Stability over time of serum antibody levels to human papillomavirus type 16.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

The serological response to papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Natural history of cervicovaginal papillomavirus infection in young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

Cervical Coinfection with Human Papillomavirus (HPV) Types as a Predictor of Acquisition and Persistence of HPV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365540903501608

10.3109/00365540903501608

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017